TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28007027
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with vancomycin-loaded calcium sulfate and vancomycin-loaded PMMA
Study: 28007027
Drug: Antibiotic-loaded PMMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic-loaded PMMA (Control Group)
Study: 28007741
Drug: Intravascular ultrasound-guided
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravascular ultrasound-guided drug-eluting stents implantation with ASM
Study: 28007741
Drug: Intravascular ultrasound-guided
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravascular ultrasound-guided drug-eluting stents implantation without ASM
Study: 28011051
Drug: Neoadjuvant temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant temozolomide (TMZ) at a daily dose of 75 mg/m²
Study: 28011608
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for Mycobacterium abscessus lung disease
Study: 28012848
Drug: Fluorescently labeled
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorescently labeled peptide (76.4 μmol/L) administered topically to proximal colon
Study: 28012848
Drug: Fluorescently labeled
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorescently labeled peptide (2.25 μmol/L and 76.4 μmol/L) administered topically to proximal colon
Study: 28013265
Drug: High drug
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High drug exposure to Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC)
Study: 28013265
Drug: Low drug
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low drug exposure to Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC)
Study: 28013405
Drug: D2C7-(scdsFv)-PE38KDEL (D2C7-IT)
Normalized name: D2C7 immunotoxin
DrugBank: D2C7 immunotoxin (DB17540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D2C7-(scdsFv)-PE38KDEL (D2C7-IT) administered via intratumoral convection-enhanced delivery for 72 hours.
Study: 28017350
Drug: hs-cTnT ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnT ≥ 14 ng/l
Study: 28017350
Drug: hs-cTnT <
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnT < 14 ng/l, overweight
Study: 28017350
Drug: hs-cTnT <
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnT < 14 ng/l, obese
Study: 28017350
Drug: hs-cTnT ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnT ≥ 14 ng/l, overweight
Study: 28017350
Drug: hs-cTnT ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnT ≥ 14 ng/l, obese
Study: 28017967
Drug: Duvelisib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duvelisib and Venetoclax combination
Study: 28018669
Drug: Omeprazole-clopidogrel combination
Normalized name: omeprazole, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole-clopidogrel combination
Study: 28018669
Drug: Pantoprazole-clopidogrel combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole-clopidogrel combination
Study: 28025928
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care using the Dader Method
Study: 28029055
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hsTnT, NT-proBNP, and hsCRP with the GRACE score
Study: 28029383
Drug: M-BET (multicomponent
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-BET (multicomponent behavioral treatment and exercise therapy)
Study: 28029383
Drug: α-blocker (tamsulosin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-blocker (tamsulosin, 0.4-mg tablet nightly)
Study: 28029383
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (M-BET + α-blocker)
Study: 28029529
Drug: Ledipasvir (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir (90 mg) plus sofosbuvir (400 mg) fixed-dose combination tablet once daily for 6 weeks
Study: 28029918
Drug: Selumetinib (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib (20 to 30 mg/m², administered twice daily on a continuous dosing schedule in 28-day cycles)
Study: 28029927
Drug: Chimeric antigen
Normalized name: Chimeric antigen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric antigen receptor (CAR)-engineered T cells targeting IL13Rα2, administered multiple times over 220 days through intracranial delivery routes.
Study: 28030578
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of non-right axis deviation, NT-proBNP<333pg/ml, SO2≥95.5%, and WHO functional class I-II
Study: 28030579
Drug: Faldaprevir 120
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 120 mg and Deleobuvir 600 mg (Child-Pugh A) or 400 mg (Child-Pugh B) twice-daily with weight-based ribavirin for 24 weeks
Study: 28031441
Drug: M5.15 activity
Approvals — FDA: no, EMA: no, PMDA: no
Description: M5.15 activity in patients responding to treatment
Study: 29065923
Drug: Intragastric balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intragastric balloon (IGB) treatment for 6 months
Study: 28031816
Drug: Ipilimumab at
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab at 3 mg/kg with peginterferon alfa-2b at 2 μg/kg/week
Study: 28032129
Drug: Oral crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral crizotinib at dose levels of 100, 130, 165, 215, 280 and 365 mg/m
Study: 28032216
Drug: Aprepitant 125/80/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 125/80/80 mg on a Monday, Wednesday, Friday schedule and oral ondansetron 8 mg po q12 h
Study: 28034990
Drug: Alisertib administered
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib administered for 7 days after conventional induction with cytarabine and idarubicin
Study: 28034993
Drug: Lenalidomide combined
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide combined with intensive chemotherapy (daunorubicin 45 mg/m2)
Study: 28034993
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy (daunorubicin 45 mg/m2)
Study: 28039079
Drug: Post-transplant cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-transplant cyclophosphamide 50 mg/kg (days +3 and +4) and tacrolimus/mycophenolate mofetil (T/MMF) (day +5 forward)
Study: 28039079
Drug: Post-transplant cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-transplant cyclophosphamide + T/MMF combination
Study: 28039155
Drug: Cabazitaxel plus
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel plus abiraterone plus prednisone (5 mg twice daily)
Study: 28039250
Drug: L-view scoring
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-view scoring system
Study: 28039250
Drug: Paired T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paired T and L-view scores
Study: 28039295
Drug: 3rd-generation CAR-T
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3rd-generation CAR-T cells (1 million CAR-T cells per kg administered intravenously)
Study: 28039295
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg intravenously every 6 hours) or IgG
Study: 28041583
Drug: Ofatumumab plus
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab plus miniCHOP regimen (1000 mg total dose of intravenous ofatumumab, 25 mg/m2 of cyclophosphamide, doxorubicin, vincristine, and prednisone) with pre-phase treatment (oral vincristine 1 mg total dose 1 week before cycle 1 and oral prednisone 60 mg total dose for 4 days before cycle 1)
Study: 28041583
Drug: Pre-phase treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-phase treatment (oral vincristine and oral prednisone)
Study: 28044265
Drug: Ranolazine 1000
Normalized name: ranolazine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine 1000 mg twice daily for 15 weeks
Study: 28045712
Drug: Option B+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Option B+ (lifelong antiretroviral therapy)
Study: 28045923
Drug: Bevacizumab in
Normalized name: bevacizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab in addition to chemotherapy
Study: 28049490
Drug: Balixafortide (POL6326)
Normalized name: Motixafortide
DrugBank: Balixafortide (DB15370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balixafortide (POL6326) at doses of 500-2500 µg/kg
Study: 28050885
Drug: pl-VEGF165 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: pl-VEGF165 gene therapy (2 intramuscular injections for a total dose of 2.4 mg)
Study: 28050885
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy without prostaglandins and prostacyclins (Control group)
Study: 28053173
Drug: Indicator amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indicator amino acid oxidation (IAAO) technique with l-[1-13C]Leucine
Study: 28053674
Drug: Eccentric Training
Normalized name: SYRINGE 60ML ECCENTRIC TIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eccentric Training + Dietary Supplement (MCVC)
Study: 28053674
Drug: Passive Stretching
Normalized name: Mederma Stretch Mark Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive Stretching + Dietary Supplement (MCVC)
Study: 28053986
Drug: Preoperative chemical
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemical vestibular ablation with 1.0 mL of 40 mg/mL nonbuffered gentamicin in three intratympanic installations over 2 days, 2 months preoperatively
Study: 28056937
Drug: Serum albumin
Normalized name: Serum albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum albumin level <3.5 g/dL
Study: 28057644
Drug: Topical cysteamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cysteamine 0.55% eye drops
Study: 28057654
Drug: Hypoxia exposure
Normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoxia exposure (3-hour exposure simulating altitude of 4000 m.a.s.l.)
Study: 28060205
Drug: Emotional self-awareness
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emotional self-awareness treatment (8 lessons with psychoeducational information and skill-building exercises)
Study: 28060358
Drug: First-generation retinal
Normalized name: retinaldehyde
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation retinal implant Alpha IMS
Study: 28060358
Drug: Next-generation retinal
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Next-generation retinal implant (under assessment in a second clinical trial)
Study: 28062705
Drug: PAK4 allosteric
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAK4 allosteric modulators (PAMs) including KPT-7523, KPT-7189, KPT-8752, KPT-9307, and KPT-9274
Study: 28063459
Drug: Angiotensin enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin enzyme converting inhibitors (86% of patients)
Study: 28063459
Drug: Beta-blockers (84%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (84% of patients)
Study: 28063717
Drug: Intravenous lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lipid emulsions (LE)
Study: 28066274
Drug: 10 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 sessions standardized pain-focused EMDR in addition to treatment-as-usual (TAU)
Study: 28068212
Drug: HZ/su vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HZ/su vaccine (2 doses, 2 months apart)
Study: 28068465
Drug: Bipolar disorder
Normalized name: INVESTIGATIONAL DRUGS FOR MANIA AND BIPOLAR DISORDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bipolar disorder without psychotropic treatment (BD-)
Study: 28068480
Drug: NeoCart implant
Normalized name: Neocartilage
DrugBank: Neocartilage (DB05257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeoCart implant
Study: 28068779
Drug: Venlafaxine, up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine, up to 300 mg/day for approximately 12 weeks
Study: 28069017
Drug: CyberKnife SBRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyberKnife SBRT at doses of 7 Gy, 7.5 Gy, 8 Gy, 8.5 Gy, 9 Gy, 9.5 Gy x 5
Study: 28069358
Drug: Pneumococcal polysaccharide
Normalized name: pneumococcal polysaccharides (23)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal polysaccharide vaccine (PPSV) administered within 10 days after neurotrauma or neurosurgery
Study: 28069358
Drug: Pneumococcal polysaccharide
Normalized name: pneumococcal polysaccharides (23)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal polysaccharide vaccine (PPSV) administered after ≥3 weeks post neurotrauma or neurosurgery (control group)
Study: 28070715
Drug: Elotuzumab in
Normalized name: elotuzumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elotuzumab in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone
Study: 28070715
Drug: Elotuzumab monotherapy
Normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Elotuzumab monotherapy
Study: 28070718
Drug: PF-06263507 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06263507 at 0.05 to 6.5 mg/kg
Study: 28070720
Drug: AZD4547 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4547 (40 mg bid to 120 mg bid; 160 mg qd in Part A; 80 mg bid in Part B)
Study: 28072473
Drug: Obinutuzumab 1000
Normalized name: obinutuzumab 1000 MG in 40 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obinutuzumab 1000 mg i.v. on Days 1, 8, and 15 of Cycle 1 (first infusion split over 2 days for CLL patients) and on Day 1 of Cycles 2-8 (21 days per cycle).
Study: 28073993
Drug: Daily goal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily goal establishment of mechanical ventilation (Phase I)
Study: 28073993
Drug: Web-based data
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based data visualization system (T3) for daily goals of mechanical ventilation (Phase II)
Study: 28073993
Drug: Combined interventions
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined interventions (Daily goal formation and T3)
Study: 28076247
Drug: Levofloxacin 750
Normalized name: levofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 750 mg intravenously/by mouth once daily for 5 days
Study: 28076247
Drug: Ciprofloxacin 400/500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 400/500 mg intravenously/by mouth twice daily for 10 days
Study: 28076966
Drug: Everolimus once
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus once daily + sorafenib twice daily (continuous schedule)
Study: 28077384
Drug: High-potency statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-potency statin (≥40 mg atorvastatin, ≥20 mg rosuvastatin, or 80 mg simvastatin daily)
Study: 28077384
Drug: Low-density lipoprotein
Normalized name: Low-density lipoprotein receptor kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-density lipoprotein cholesterol <70 mg/dL at 3 months
Study: 28078107
Drug: Bevacizumab added
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab added to induction chemotherapy and concurrent chemoradiation with cisplatin/irinotecan
Study: 28078750
Drug: Prebiotic (2.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic (2.8 g/day HOST-G904)
Study: 28079870
Drug: l-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-carnitine supplementation added to parenteral nutrition in 390 (39%) study subjects
Study: 28079870
Drug: l-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-carnitine supplementation
Study: 28081162
Drug: Interventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interventional treatment (stenting and/or balloon angioplasty)
Study: 28081820
Drug: DAPT (aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT (aspirin plus thienopyridine)
Study: 28081914
Drug: Pembrolizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (10 mg/kg intravenous every 2 weeks until disease progression or unacceptable toxic effects)
Study: 28081953
Drug: 1 regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 regimen of chemotherapy
Study: 28081953
Drug: >1 regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: >1 regimen of chemotherapy
Study: 28081953
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies in addition to chemotherapy
Study: 28082379
Drug: Five years
Normalized name: HISTA-FIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five years of specialised early intervention (SEI) treatment (n=197)
Study: 28082379
Drug: Two years
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two years of specialised early intervention (SEI) plus three years of treatment as usual (control; n=203)
Study: 28082419
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy for primary prevention of SCD
Study: 28084038
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ranibizumab injections monthly
Study: 28084683
Drug: High antibiotic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High antibiotic use
Study: 29497747
Drug: Combined Aphasia
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Aphasia and Apraxia of Speech Treatment (CAAST)
Study: 28086010
Drug: Dose reduction
Normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reduction of antipsychotics (olanzapine or risperidone) by up to 40%
Study: 28086754
Drug: Nutritional status,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional status, nutritional risk; disease conditions, medication, and diet prescriptions; oral health exam, signs of swallowing difficulty and olfactory ability; observed eating behaviours, type and number of staff assisting with eating; food and foodservice satisfaction.
Study: 28086870
Drug: Motivational Interviewing-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Interviewing-based counseling by community health agents (CHAs)
Study: 28086942
Drug: Conventionally fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally fractionated radiotherapy (cfRT) at dose level 1 (54Gy)
Study: 28086942
Drug: Conventionally fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally fractionated radiotherapy (cfRT) at dose level 2 (58Gy)
Study: 28086942
Drug: Conventionally fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally fractionated radiotherapy (cfRT) at dose level 3 (62Gy)
Study: 28086942
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with cfRT
Study: 28086942
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with cfRT at dose level 3 (62Gy)
Study: 28087181
Drug: 1h algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1h algorithm with hs-TnI cutoff of 6ng/L
Study: 28087181
Drug: 99th percentile
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99th percentile cutoff of 27ng/L
Study: 28087556
Drug: Warfarin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin treatment in patients with blunt head injury
Study: 28088395
Drug: Serum lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum lactate ≥ 2.5 mmol/L
Study: 28088395
Drug: Lactate: pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate: pyruvate (L:P) ratio ≥ 25
Study: 28088395
Drug: Initial lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial lactate or L:P
Study: 28089238
Drug: Ruxolitinib 10
Normalized name: ruxolitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 10 mg orally twice a day
Study: 28089618
Drug: Continuous (par)enteral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous (par)enteral nutrition with protein intake 1.0-3.7 g/kg/day
Study: 28089635
Drug: Venetoclax (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (400 mg recommended phase 2 dose) plus rituximab (375 mg/m2 monthly)
Study: 28089635
Drug: Venetoclax (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (400 mg) plus rituximab
Study: 28089635
Drug: Venetoclax (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (50 mg)
Study: 28089635
Drug: Venetoclax (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (20 mg)
Study: 28089762
Drug: Concurrent weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Concurrent weekly carboplatin and paclitaxel with 74 Gy of radiation in 37 fractions (2-Gy daily fractions)
Study: 28090295
Drug: Inhaled trepostinil
Normalized name: treprostinil Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled trepostinil
Study: 28090299
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg/day for the first 4 weeks, then 40 mg/day for the subsequent 20 weeks
Study: 28090335
Drug: Top-down treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Top-down treatment with 5 Infliximab (IFX) infusions combined with azathioprine (AZA).